2009
Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism
Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism. Respiratory Medicine 2009, 103: 951-962. PMID: 19304472, DOI: 10.1016/j.rmed.2009.02.016.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionEndothelin receptor antagonistsArterial hypertensionET-1Development of PAHManagement of PAHPathogenesis of PAHEndothelin receptor blockadeLiver function abnormalitiesPlacebo-controlled trialNitric oxide-mediated pathwayClinical study resultsGood clinical resultsClinical treatment studiesUnited States FoodPeripheral edemaFunction abnormalitiesReceptor blockadeDual antagonismDual blockadeSafety profileET receptorsEndothelin-1Head studiesReceptor antagonist
2005
Treating Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension: Is Endothelin 1 a Target?
Trow T. Treating Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension: Is Endothelin 1 a Target? Clinical Pulmonary Medicine 2005, 12: 196-197. DOI: 10.1097/01.cpm.0000163121.24487.48.Peer-Reviewed Original ResearchHuman immunodeficiency virus-associated pulmonary arterial hypertensionNew York Heart Association functional classPulmonary arterial hypertensionPulmonary hypertensionCardiopulmonary hemodynamicsQuality-of-life measuresArterial hypertensionEndothelin-1Treated patientsDrug interactionsSide effectsFunctional classBosentanWalking distanceHypertensionEndothelinPatientsHemodynamics